Regulatory Goes Digital: Chapter 5 in Our Series on Drug Development Data
In the final chapter of our series, Yash dives into one of the biggest upcoming shifts in drug development’s data paradigm: moving to structured, cloud-based regulatory submissions.
Data Governance and Integrity: Pharma, Biotech, and the Data Deluge, Part 4
In chapter 4 of our series on drug development data, Yash looks at a practical application of structured data principles: building a digital qTPP that supports automation of numerous CMC tasks.
Data Governance and Integrity: Pharma, Biotech, and the Data Deluge, Part 3
Scrambling to consolidate CMC data often feels like a rite of passage for drug developers. But does it have to be that way? In post 3 of our series on data governance and integrity, Yash shares a modern, structured approach to managing CMC data.
Data Governance and Integrity: Pharma, Biotech, and the Data Deluge, Part 2
In post #2 of our data governance series, we look at the kind of information frameworks drug developers should consider as they work to fully maximize the integrity and value of their data.
How Our Partners at AWS Keep Drug Development Data Safe in the Cloud
Questions about security and compliance continue to hold many drug developers back from adopting cloud-based solutions. Our CTO Ryan Shillington sat down with AWS solution architect Reef D’Souza to talk about some of their most common concerns.
QbDVision and ZAETHER Team Up To Accelerate Digital Transformation
Our team of digital CMC experts is thrilled to be joining forces with one of the life sciences’ leading transformation consultancies. Find out how we aim to help customers achieve new levels of efficiency, integration, and productivity.
Data Governance and Integrity: Pharma, Biotech, and the Data Deluge, Part 1
Today’s drug developers are deluged with unstructured data. In this first post of a new series, find out how pharma and biotech companies are struggling to manage their information resources.
